132 related articles for article (PubMed ID: 17108214)
1. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
Taback B; Giuliano AE; Lai R; Hansen N; Singer FR; Pantel K; Hoon DS
Ann N Y Acad Sci; 2006 Sep; 1075():211-21. PubMed ID: 17108214
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
3. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
[TBL] [Abstract][Full Text] [Related]
4. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
Taback B; Giuliano AE; Hansen NM; Singer FR; Shu S; Hoon DS
Cancer Res; 2003 Apr; 63(8):1884-7. PubMed ID: 12702578
[TBL] [Abstract][Full Text] [Related]
5. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
6. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
Hu XC; Wong IH; Chow LW
Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
[TBL] [Abstract][Full Text] [Related]
9. Prognostic DNA methylation marker in serum of cancer patients.
Müller HM; Fiegl H; Widschwendter A; Widschwendter M
Ann N Y Acad Sci; 2004 Jun; 1022():44-9. PubMed ID: 15251938
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
Müller HM; Widschwendter A; Fiegl H; Ivarsson L; Goebel G; Perkmann E; Marth C; Widschwendter M
Cancer Res; 2003 Nov; 63(22):7641-5. PubMed ID: 14633683
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
[TBL] [Abstract][Full Text] [Related]
15. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
16. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue.
Yan PS; Venkataramu C; Ibrahim A; Liu JC; Shen RZ; Diaz NM; Centeno B; Weber F; Leu YW; Shapiro CL; Eng C; Yeatman TJ; Huang TH
Clin Cancer Res; 2006 Nov; 12(22):6626-36. PubMed ID: 17121881
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
Umetani N; Mori T; Koyanagi K; Shinozaki M; Kim J; Giuliano AE; Hoon DS
Oncogene; 2005 Jul; 24(29):4721-7. PubMed ID: 15897910
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
Digel W; Lübbert M
Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
20. Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer.
Wascher RA; Huynh KT; Giuliano AE; Hansen NM; Singer FR; Elashoff D; Hoon DS
Clin Cancer Res; 2003 Apr; 9(4):1427-35. PubMed ID: 12684415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
